Search results
Aug 16, 2023 · Abby Jane Golash, PharmD. Julia Rotow, MD. Daniel J. DeAngelo, MD, PhD. Mariana Castells, MD, PhD. Show all authors. Published: August 16, 2023 DOI: https://doi.org/10.1016/j.anai.2023.08.009. Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinoma.
The work of Kim et al4 revealed that the co-treatment of mast cells with melatonin nanoparticles at 1 mM concentration and the C48/80 stim-ulus inhibited beta-hexosaminidase, a preformed component of mast cell granules, by 25%, facilitating the anti-in ammatory effect of mel-fl atonin. TaggedAPTARAEnd.
The Department of Pharmacy at Brigham and Women’s Hospital ofers a specialized residency in critical care pharmacy practice. This one-year ASHP accredited program is designed to provide advanced training in the area of critical care pharmacotherapy and research.
- 1006KB
- 7
Dec 12, 2021 · Abstract. Ultrasound-facilitated catheter-directed thrombolysis is used with low-dose alteplase to treat pulmonary embolism. This reduces the risk of bleeding that accompanies systemic administration of higher alteplase doses.
- 10.1182/bloodadvances.2021005001
- 2021/12/12
- Blood Adv. 2021 Dec 14; 5(23): 5283-5289.
Abby Jane Golash, PharmD* Kathleen Marquis, PharmD, PhD* Kylie Marie Besz, MS, MPH* Geoffrey Oxnard, MDy Julia Rotow, MDz Daniel J. DeAngelo, MD, PhDz Mariana Castells, MD, PhD* *Department of Allergy and Clinical Immunology Brigham and Women’s Hospital Boston, Massachusetts y Department of Medical Oncology Boston Medical Center Boston ...
Jan 1, 2010 · Abby Jane (A.J.) Golash PharmD, P PharmD, P Senior Pharmacist Senior Pharmacist righam and Women’s Hospital, righam and Women oston, MA ’s Hospital, 2019-2020 Nicholas Hunt PharmD, P linical Specialist, ritical are, Rush University Medical enter, hicago, IL rian Schuler PharmD, P
Dec 14, 2021 · Abstract. Ultrasound-facilitated catheter-directed thrombolysis is used with low-dose alteplase to treat pulmonary embolism. This reduces the risk of bleeding that accompanies systemic administration of higher alteplase doses.
